SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investors debate its future amid discussions around government contracts, production scaling, and potential revenue from its maritime division; community sentiment is divided with some expressing frustration over missed guidance while others remain optimistic about the drone industry's growth and RCAT's position within it. Some traders are actively betting against RCAT due to management's performance and potential dilution from outstanding warrants, while others believe its long-term potential remains strong and cite the possibility of major contract wins.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

CVKD is trending due to a recent Zacks Small Cap Research report and analyst price targets. Community discussions revolve around the company's financial health, including executive compensation and potential dilution, while also highlighting a recent Frunexian acquisition. Some see a potential opportunity with positive technical indicators, while others express skepticism.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending due to its growing community and its positioning as a culture-driven token on the Solana blockchain. The community emphasizes positivity, creativity, and freedom of expression, drawing comparisons to Bitcoin but with a unique focus on cannabis culture. Discussions highlight the project's organic growth and welcoming vibe within the crypto space.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending amid discussions around its pivot to AI/HPC data centers and anticipation of potential deals, with some bullish investors drawing comparisons to IREN's recent performance. Despite mixed reactions to earnings, the company's strategic positioning and substantial power capacity are key talking points. Community members are actively debating the stock's potential and valuation, with some highlighting a possible short squeeze.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The DIA is trending as community members discuss market momentum and potential overvaluation, particularly in tech. Bullish sentiment and possible December rate cuts are being weighed against concerns of a market correction. Additionally, political and economic factors, including upcoming reports and potential government actions, contribute to the conversation around the ETF.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

IDYA is trending as investors discuss its potential in precision medicine oncology, with analysts updating ratings and price targets. Community members are closely watching the company's clinical pipeline and upcoming data readouts, particularly for darovasertib and IDE397. Discussions also include the potential for strategic partnerships and acquisitions within the biotech sector.

Elastic NV is a data analytics company, which engages in the provision of open-source search and analytics engine services. It operates through the United States, the Netherlands, United Kingdom, India, and Rest of World geographical segments. The company was founded by Shay Banon, Uri Boness, Steven Schuurman, and Simon Willnauer on February 9, 2012 and is headquartered in San Francisco, CA.

Elastic N.V

Elastic is trending following a strong earnings report, with the community noting the potential for AI-driven growth and a turnaround in execution.  Analysts have responded positively, upgrading the stock and raising price targets, while traders discuss potential breakout levels. Discussions also focus on whether the stock can sustain its momentum or if a pullback is imminent.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex ($SCLX) is trending amid discussions about its Bitcoin-backed investment in Datavault AI ($DVLT) and the upcoming distribution of a meme coin dividend. Community members are debating the implications of SCLX's ownership stake in DVLT, potential dilution, and the overall value of the deal, while some express skepticism and draw comparisons to past events involving Sorrento Therapeutics.

Quai is a merge-mined network of blockchains. This network is able to coordinate an infinite number of blockchains (execution shards) by using the Proof-of-Entropy-Minima (PoEM) consensus mechanism, which eliminates all consensus-based contention. The ability for PoEM to coordinate a perpetually growing set of blockchains allows the network to process more than 50,000 transactions per second. The architecture is a composable multithreaded execution environment with blocks being produced approximately every 1.1 seconds.

Quai Network

Quai Network is trending as investors discuss its potential Kraken listing and unique approach to scalability and energy efficiency. Community members highlight its innovative technology, real-world asset applications, and potential for significant growth, while also acknowledging current token unlock pressures. Discussions also focus on Quai Network's potential as a key player in the future of Web3, AI, and decentralized infrastructure.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet ($STRK) is gaining attention due to significant staking incentives, particularly its Bitcoin staking program, attracting substantial capital and increasing network activity. The community is actively discussing Starknet's potential to scale Bitcoin and Ethereum with privacy features, as well as its quantum-resistant technology. Technical analysis suggests a possible breakout, further fueling community interest in its potential as a leading Layer-2 solution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Invivyd (NASDAQ:IVVD) Trading Down 6% - Here's Why

Invivyd (NASDAQ:IVVD) Shares Down 6% - What's Next...

Invivyd (NASDAQ:IVVD) Earns Hold Rating from D. Boral Capital

D. Boral Capital reaffirmed a "hold" rating on shares of Invivyd in a research note on Tuesday...

Invivyd (NASDAQ:IVVD) Director Kevin Mclaughlin Acquires 50,000 Shares

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Kevin Mclaughlin bought 50,000 shares of the stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an...

Insider Buying: Invivyd (NASDAQ:IVVD) Director Acquires 50,000 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Kevin Mclaughlin purchased 50,000 shares of Invivyd stock in a transaction on Wednesday, November 19th. The stock was bought at an average price...

Invivyd (NASDAQ:IVVD) Shares Gap Down - Time to Sell?

Invivyd (NASDAQ:IVVD) Shares Gap Down - Time to Sell...

Invivyd (NASDAQ:IVVD) Sees Strong Trading Volume - Here's What Happened

Invivyd (NASDAQ:IVVD) Sees Unusually-High Trading Volume - Time to Buy...

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<ul class="summary-bullets"><li>The company launched an underwritten public stock offering, granting underwriters a 30-day option to buy additional shares.</li><li>Invivyd said proceeds will support preparation for a potential VYD2311 launch and broader pipeline development.</li><li>Recent filings showed the firm posted higher Q3 revenue and a sharply narrower quarterly net loss.</li></ul><p>Invivyd, Inc. shares surged to a 19-month high on Monday after investors welcomed the company’s move to launch a public stock offering, following fresh ownership filings from Point72 and Janus Henderson.</p><p>The stock rose 21% to $2.84 on Monday, extending the prior session’s rally after the stake disclosures, which had driven the stock to its strongest one-day gain in nearly three months. However, shares slipped 8.6% in after-hours trade.</p><h2 class="st-heading-2"><strong>Public Offering Announcement</strong></h2><p>Invivyd said it had launched an offering of its common stock and would grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold. Cantor is serving as&nbsp;the sole book-running manager.</p><p>The company said it intends to use proceeds, together with existing cash, to prepare for a potential launch of VYD2311, its investigational monoclonal antibody designed for the prevention and treatment of&nbsp;COVID-19. Proceeds will also support research and development across programs, including RSV and measles, advance its SPEAR study group focused on monoclonal antibody therapy in Long Covid and Covid-19 post-vaccination syndrome, and fund general corporate purposes.</p><h2 class="st-heading-2"><strong>Large Stake Filings Released Last Week</strong></h2><p>Point72 Asset Management and CEO Steven A. Cohen disclosed beneficial ownership of 9.7%, representing 20.37 million shares, while Janus Henderson Group reported a 12.1% position totaling 25.38 million shares. Both filings listed shared voting and dispositive power over their holdings.</p><h2 class="st-heading-2"><strong>Q3 Review</strong></h2><p>Invivyd reported third-quarter (Q3) revenue of $13.1 million, up from $9.3 million a year earlier, and a net loss of $10.5 million, compared with $60.7 million a year ago. Loss per share narrowed to $0.06 from $0.51.</p><p>For the nine months to Sept. 30, revenue rose to $36.2 million from $11.6 million, while net loss narrowed to $41.4 million from $151.5 million, with loss per share improving to $0.30 from $1.28.</p><h2 class="st-heading-2"><strong>Antibody Activity And FDA Guidance</strong></h2><p>In August, Invivyd said its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-chatter-surges-around-invivyd-after-data-show-pemgarda-neutralizes-xfg-covid-19-variant/chsg3b8RdXH">monoclonal antibodies pemivibart and VYD2311</a> continued to neutralize the emerging XFG COVID-19 variant in laboratory tests. The company also reported activity against circulating variants NB.1.8.1, LF.7.9, and LP.8.1, and said it identified no resistant strains.&nbsp;</p><p>The company also said it had reached alignment with the FDA on a streamlined regulatory pathway for VYD2311. Following a Type C meeting, the agency advised that a single Phase 2/3 randomized, placebo-controlled trial with a modest number of symptomatic COVID-19 cases could support a biologics license application. Invivyd had said it would test two doses and has a clinical supply on hand.</p><h2 class="st-heading-2"><strong>Stocktwits Traders Brace For Larger Deal Terms</strong></h2><p>On Stocktwits, retail sentiment for Invivyd was ‘bullish’ amid a 9,000% surge in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:976/144;" src="https://news.stocktwits-cdn.com/ivvd_ss_jpg_3421872aeb.webp" alt="ivvd ss.jpg" width="976" height="144"><figcaption>IVVD sentiment and message volume as of November 17 | Source: Stocktwits</figcaption></figure><p>One user said they were holding their short and expected a large offering once the company releases the updated prospectus with the final deal terms.&nbsp;</p><p><stembedurl>https://stocktwits.com/SteelcityTrader44/message/636537231</stembedurl></p><p>Another user said the fundraising made sense, adding that bigger gains might come in 2026 and questioning the offer price.</p><p><stembedurl>https://stocktwits.com/trader2sde/message/636522548</stembedurl></p><p><a href="https://stocktwits.com/symbol/IVVD">Invivyd’s stock</a> has surged by more than 540% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Invivyd’s stock (IVVD) has surged by more than 540% so far in 2025. (Photo credit: Getty Images)

Invivyd Stock Hits 19-Month High As Public Offering Lands Days After Point72, Janus Henderson Reveal Big Stakes

Invivyd said proceeds will support preparation for a potential VYD2311 launch and broader pipeline development.

Equity

Top Penny Stocks To Add to Your Watchlist - November 16th

Leap Therapeutics, Cypherpunk Technologies, Invivyd, Bitfarms, and Beyond Meat are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced...

Invivyd (NASDAQ:IVVD) Sets New 12-Month High - Here's What Happened

Invivyd (NASDAQ:IVVD) Reaches New 12-Month High - Still a Buy...

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	--	--	N/A
Q3 '25	-$0.08	-$0.06	25.00%	BEAT
Q2 '25	-$0.02	-$0.12	-424.77%	MISSED
Q1 '25	-$0.03	-$0.14	-366.67%	MISSED
Q4 '24	-$0.20	-$0.14	30.00%	BEAT

IVVD
Invivyd Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest IVVD News

IVVDInvivyd Inc